Skip to main content
Clinical Trials/CTRI/2019/09/021152
CTRI/2019/09/021152
Completed
Phase 3

Randomized Controlled Trial to compare two different doses of Folinic acid (leucovorin) in Methotrexate Toxicity - FLIMT

PGIMER Chandigarh0 sites38 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
PGIMER Chandigarh
Enrollment
38
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1 A patient prescribed weekly or the biweekly dose of tablet or parenteral Methotrexate (up to 50 mg per week) for rheumatic or dermatologic or gastrointestinal disease
  • 2 Patient having methotrexate hematologic Toxicity defined as EITHER WBC less than 2000 AND OR Platelet count less than 50000 per microlitre (with or without mucositis)
  • 3 Either inadvertent overdose OR renal dysfunction

Exclusion Criteria

  • 1 Patient not consenting for the study
  • 2 Patient being treated with High Dose Methotrexate regimen.
  • 3 Patient \<12 years of age
  • 4 Patient already received more than one dose of folinic acid

Outcomes

Primary Outcomes

Not specified

Similar Trials